Abstract
Oxidative stress is implicated in the pathogenesis of a number of neurological disorders such as Alzheimers disease (AD), Parkinsons disease (PD), multiple sclerosis and stroke in the adult as well as in conditions such as periventricular white matter damage in the neonatal brain. It has also been linked to the disruption of blood brain barrier (BBB) in hypoxic-ischemic injury. Both experimental and clinical results have shown that antioxidants such as melatonin, a neurohormone synthesized and secreted by the pineal gland and edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a newly developed drug, are effective in reducing oxidative stress and are promising neuroprotectants in reducing brain damage. Indeed, the neuroprotective effects of melatonin in many central nervous system (CNS) disease conditions such as amyotrophic lateral sclerosis, PD, AD, ischemic injury, neuropsychiatric disorders and head injury are well documented. Melatonin affords protection to the BBB in hypoxic conditions by suppressing the production of vascular endothelial growth factor and nitric oxide which are known to increase vascular permeability. The protective effects of melatonin against hypoxic damage have also been demonstrated in newborn animals whereby it attenuated damage in different areas of the brain. Furthermore, exogenous administration of melatonin in newborn animals effectively enhanced the surface receptors and antigens on the macrophages/microglia in the CNS indicating its immunoregulatory actions. Edaravone has been shown to reduce oxidative stress, edema, infarct volume, inflammation and apoptosis following ischemic injury of the brain in the adult as well as decrease free radical production in the neonatal brain following hypoxic-ischemic insult. It can counteract toxicity from activated microglia. This review summarizes the clinical and experimental data highlighting the therapeutic potential of melatonin and edaravone in neuroprotection in various disorders of the CNS.
Keywords: Neurodegeneration, melatonin, edaravone
Current Medicinal Chemistry
Title: Antioxidants and Neuroprotection in the Adult and Developing Central Nervous System
Volume: 15 Issue: 29
Author(s): Charanjit Kaur and Eng-Ang Ling
Affiliation:
Keywords: Neurodegeneration, melatonin, edaravone
Abstract: Oxidative stress is implicated in the pathogenesis of a number of neurological disorders such as Alzheimers disease (AD), Parkinsons disease (PD), multiple sclerosis and stroke in the adult as well as in conditions such as periventricular white matter damage in the neonatal brain. It has also been linked to the disruption of blood brain barrier (BBB) in hypoxic-ischemic injury. Both experimental and clinical results have shown that antioxidants such as melatonin, a neurohormone synthesized and secreted by the pineal gland and edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a newly developed drug, are effective in reducing oxidative stress and are promising neuroprotectants in reducing brain damage. Indeed, the neuroprotective effects of melatonin in many central nervous system (CNS) disease conditions such as amyotrophic lateral sclerosis, PD, AD, ischemic injury, neuropsychiatric disorders and head injury are well documented. Melatonin affords protection to the BBB in hypoxic conditions by suppressing the production of vascular endothelial growth factor and nitric oxide which are known to increase vascular permeability. The protective effects of melatonin against hypoxic damage have also been demonstrated in newborn animals whereby it attenuated damage in different areas of the brain. Furthermore, exogenous administration of melatonin in newborn animals effectively enhanced the surface receptors and antigens on the macrophages/microglia in the CNS indicating its immunoregulatory actions. Edaravone has been shown to reduce oxidative stress, edema, infarct volume, inflammation and apoptosis following ischemic injury of the brain in the adult as well as decrease free radical production in the neonatal brain following hypoxic-ischemic insult. It can counteract toxicity from activated microglia. This review summarizes the clinical and experimental data highlighting the therapeutic potential of melatonin and edaravone in neuroprotection in various disorders of the CNS.
Export Options
About this article
Cite this article as:
Kaur Charanjit and Ling Eng-Ang, Antioxidants and Neuroprotection in the Adult and Developing Central Nervous System, Current Medicinal Chemistry 2008; 15 (29) . https://dx.doi.org/10.2174/092986708786848640
DOI https://dx.doi.org/10.2174/092986708786848640 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Potential of Minocycline for Schizophrenia
CNS & Neurological Disorders - Drug Targets Relevance of the Chronobiological and Non-chronobiological Actions of Melatonin for Enhancing Therapeutic Efficacy in Neurodegenerative Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery A Cross-entropy-based Method for Essential Protein Identification in Yeast Protein-protein Interaction Network
Current Bioinformatics Sensory-Motor Integration in the Medial Medulla
Current Neuropharmacology Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Amyloid Beta Peptide, 4-Hydroxynonenal and Apoptosis
Current Alzheimer Research Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
CNS & Neurological Disorders - Drug Targets Regulation of GABA Neurotransmission by Glutamic Acid Decarboxylase (GAD)
Current Pharmaceutical Design Consideration of a Pharmacological Combinatorial Approach to Inhibit Chronic Inflammation in Alzheimer’s Disease
Current Alzheimer Research Prostaglandins and Cyclooxygenases in Glial Cells During Brain Inflammation
Current Drug Targets - Inflammation & Allergy The Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease
Current Alzheimer Research Organelle Stress Sensors and Cell Death Mechanisms in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets Integrating Qualitative and Quantitative Tools for the Detection and Identification of Lectins in Major Human Diseases
Protein & Peptide Letters Updating the Chemistry and Biology of Cannabinoid CB2 Receptor – Specific Inverse Agonists
Current Topics in Medicinal Chemistry Is rTMS an Effective Therapeutic Strategy that Can Be Used to Treat Parkinson's Disease?
CNS & Neurological Disorders - Drug Targets Signaling Mechanisms Underlying Aβ Toxicity: Potential Therapeutic Targets for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Past, Present and Future Drugs for the Treatment of Obsessive- Compulsive Disorder
Current Medicinal Chemistry FTD and ALS: A Tale of Two Diseases
Current Alzheimer Research Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?
Current Neuropharmacology